Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

20 November 2018

Coalities nodig voor betere toegang tot medicijnen

Writing for the NRC, Daan van Lent covers the publication of the 2018 Access to Medicine Index. The article highlights the industry's engagement in priority R&D and the small number of companies developing vital projects.

Direct links

Read the full article

The piece also emphasises the importance of collaboration between large pharmaceutical companies, governments and donors to improve access to medicine for people living in poorer countries. Daan quotes Jayasree K. Iyer, Executive Director of the Access to Medicine, on the fight against malaria as a good example of such collaboration: "The common goal is to have the disease banned in 2030. The pharmaceutical companies have decided not to make any profit on the malaria drugs. That is a recipe for success."

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved